Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma
Neoadjuvant immunotherapy improved survival outcomes in patients with advanced resectable pCSCC. These findings underscore the importance of including this patient population in upcoming randomized trials.
Authors
- Renata Ferrarotto (ORCID: https://orcid.org/0000-0002-3561-215X)
- Priyadharsini Nagarajan (ORCID: https://orcid.org/0000-0002-5346-2669)
- Paul W. Gidley (ORCID: https://orcid.org/0000-0003-3706-8781)
- Moran Amit (ORCID: https://orcid.org/0000-0002-9720-7766)
- Neil D. Gross (ORCID: https://orcid.org/0000-0002-9427-0743)
- David Z. Allen (ORCID: https://orcid.org/0000-0002-6727-4378)
- Marc‐Elie Nader (ORCID: https://orcid.org/0000-0001-9295-0174)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Head & Neck
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1002/hed.70080
- Citations
- 1
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute